Latest Recruitment News

Dimerix CEO Dr Nina Webster detailed the company’s geographic and product diversification at the Bioshares Summit, spotlighting the commercial potential of DMX-200 and the newly acquired Phase 2 asset DMX-652 targeting acute kidney injury.

Clarity Pharmaceuticals reveals encouraging early results from the SECuRE trial, with substantial PSA reductions and multiple complete responses at the 8 GBq 67Cu-SAR-bisPSMA dose level in advanced prostate cancer patients.

Centrepoint Alliance reported a 16% rise in normalised EBITDA to $12.3 million for FY26, exceeding its guidance and lifting its EBITDA margin to 29%. The company’s adviser network grew modestly, while funds under management jumped 48%.

Clarity Pharmaceuticals bolsters its commercial readiness with a $178.3 million cash reserve and a key US manufacturing agreement, while clinical trials for its prostate cancer imaging and therapeutic agents progress with promising data.

Eden Innovations reported strong EdenCrete® trial results in India and North America, strategic hires for EdenShield® in defence markets, and completed a $4.05 million placement, ending the quarter debt-free with $5.2 million cash.

Tissue Repair advances its US Phase III chronic wound trial with 100 patients randomised and targets October FDA 510(k) submission. The company reports a robust cash position bolstered by R&D refunds and has cut manufacturing scale-up costs.

OpenLearning Limited posted a record $3.27 million in SaaS annual recurring revenue and its highest quarterly cash receipts of $1.653 million, driven by new multi-year contracts in the Philippines and Malaysia and launches of AI-driven student recruitment and employability platforms.

Dimerix Limited (ASX: DXB) has inked its fifth regional licensing agreement with Everest Medicines, boosting potential milestone payments to A$1.9 billion and expanded its kidney disease pipeline through the acquisition of DMX-652. The Phase 3 ACTION3 trial for DMX-200 remains statistically robust, with funding secured to advance both clinical programs.

Epiminder has leveraged its $125 million IPO to advance clinical enrolments, boost Medicare reimbursement, and develop its next-generation Minder device, positioning for a commercial launch in early 2028.

Avecho Biotechnology has secured a unanimous recommendation to continue its Phase III insomnia trial without increasing sample size, alongside raising $1.9 million through option exercises and bolstering its cash position to $6.6 million.

Emyria has expanded its Empax clinic network across four states, reporting a 210% revenue increase in FY26 and early clinical success in treatment-resistant depression.

Biome Australia capped FY26 with record $23.9 million sales and its flagship probiotic topping Australian pharmacy charts. The company signed an onshore manufacturing deal and expanded its proprietary probiotic clinical trial internationally.